Effect of Hemodialysis on Hepatic Cytochrome P450 Functional Expression

Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of...

Full description

Saved in:
Bibliographic Details
Published inJournal of Pharmacological Sciences Vol. 108; no. 2; pp. 157 - 163
Main Authors Michaud, Josée, Nolin, Thomas D., Naud, Judith, Dani, Mélina, Lafrance, Jean-Philippe, Leblond, Francois A., Himmelfarb, Jonathan, Pichette, Vincent
Format Journal Article
LanguageEnglish
Published Japan Elsevier B.V 2008
The Japanese Pharmacological Society
Elsevier
Subjects
Online AccessGet full text
ISSN1347-8613
1347-8648
DOI10.1254/jphs.08042FP

Cover

Abstract Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-κB (NF-κB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-κB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-κB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum.
AbstractList Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-κB (NF-κB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-κB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-κB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum.
Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-KB (NF-кB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-кB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-кB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum.
Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-κB (NF-κB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-κB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-κB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum. Keywords:: hemodialysis, end-stage renal disease, cytochrome P450, gene expression, drug metabolism
Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-kappaB (NF-kappaB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-kappaB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-kappaB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum.
Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-kappaB (NF-kappaB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-kappaB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-kappaB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum.Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-kappaB (NF-kappaB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-kappaB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-kappaB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum.
Author Nolin, Thomas D.
Pichette, Vincent
Michaud, Josée
Lafrance, Jean-Philippe
Dani, Mélina
Himmelfarb, Jonathan
Leblond, Francois A.
Naud, Judith
Author_xml – sequence: 1
  givenname: Josée
  surname: Michaud
  fullname: Michaud, Josée
  organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4
– sequence: 2
  givenname: Thomas D.
  surname: Nolin
  fullname: Nolin, Thomas D.
  organization: Division of Nephrology and Transplantation, Department of Medicine, Maine Medical Center, Portland, ME 04102, USA
– sequence: 3
  givenname: Judith
  surname: Naud
  fullname: Naud, Judith
  organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4
– sequence: 4
  givenname: Mélina
  surname: Dani
  fullname: Dani, Mélina
  organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4
– sequence: 5
  givenname: Jean-Philippe
  surname: Lafrance
  fullname: Lafrance, Jean-Philippe
  organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4
– sequence: 6
  givenname: Francois A.
  surname: Leblond
  fullname: Leblond, Francois A.
  organization: Division of Nephrology and Transplantation, Department of Medicine, Maine Medical Center, Portland, ME 04102, USA
– sequence: 7
  givenname: Jonathan
  surname: Himmelfarb
  fullname: Himmelfarb, Jonathan
  organization: Division of Nephrology and Transplantation, Department of Medicine, Maine Medical Center, Portland, ME 04102, USA
– sequence: 8
  givenname: Vincent
  surname: Pichette
  fullname: Pichette, Vincent
  email: vpichette.hmr@ssss.gouv.qc.ca
  organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4
BackLink https://www.ncbi.nlm.nih.gov/pubmed/18845914$$D View this record in MEDLINE/PubMed
BookMark eNptUj1v2zAQFYoUzUe7dS40dapTfomixsK1kwABmqGdiTN1jGnIoktKRf3ve7YcD0UGnUjp3XvH93hdXPSxx6L4yNktF5X6utmt8y0zTInl05viiktVz4xW5uK85vKyuM55w5gwjOt3xSU3RlUNV1fF3cJ7dEMZfXmP29gG6PY55DL2tN_BEFw53w_RrVPcYvmkKlYux94NIfbQlYu_u4Q50-Z98dZDl_HD6X1T_Foufs7vZ48_7h7m3x5nrpbVMEPNVV0jc1gL5wWIlZReQo24qoC3vKpdI41ohUdN4zrnPLbA_IpLD1rV8qZ4mHjbCBu7S2ELaW8jBHv8ENOzhURTd2hBttK0xCzIB62YQRRYAzeVkthWnrg-T1y7FH-PmAe7Ddlh10GPccxWN7ohcEPATyfguNpie5Z9sZEAYgK4FHNO6K0LAxxMGhKEznJmD1nZQ1b2lBU1ffmv6cz7OnwxwWmC4KCLfRd6tJs4JooiW-d1dgF7KxgzlnHqE5YdHnKVipZNUzWHw3yfeDZ5gGc8i77YdhSlbiuO9SR__u3WkCz2RKMnGqS0_wRM9qjuaLhEF4riCK-f4x9_9dbJ
CitedBy_id crossref_primary_10_1002_jps_22640
crossref_primary_10_1124_dmd_116_070052
crossref_primary_10_3390_toxins11040209
crossref_primary_10_1186_s40360_018_0221_6
crossref_primary_10_1002_jcph_2043
crossref_primary_10_1016_j_banm_2022_10_018
crossref_primary_10_1021_acs_molpharmaceut_9b00459
crossref_primary_10_1586_ecp_11_66
crossref_primary_10_1016_j_jpba_2020_113202
crossref_primary_10_1016_j_pharep_2018_12_007
crossref_primary_10_1111_1744_9987_12100
crossref_primary_10_1080_00498254_2021_1909783
crossref_primary_10_1093_ndt_gfad038
crossref_primary_10_3390_toxins5081475
crossref_primary_10_1002_cpt_1875
crossref_primary_10_1124_dmd_113_054171
crossref_primary_10_3851_IMP2941
crossref_primary_10_1177_0091270011415410
crossref_primary_10_36290_vnl_2020_057
crossref_primary_10_5604_01_3001_0012_7868
crossref_primary_10_1111_sdi_12484
crossref_primary_10_1007_s00228_009_0678_8
crossref_primary_10_1007_s40262_014_0146_1
crossref_primary_10_1517_17425255_2013_835802
crossref_primary_10_1038_clpt_2009_163
crossref_primary_10_1038_s41374_021_00610_9
crossref_primary_10_1248_yakushi_132_461
crossref_primary_10_1002_cpdd_238
crossref_primary_10_1053_j_ackd_2015_10_002
crossref_primary_10_1016_j_semnephrol_2014_02_010
crossref_primary_10_1002_jcph_349
crossref_primary_10_1016_j_semnephrol_2012_12_016
crossref_primary_10_3390_ijms252212279
crossref_primary_10_1096_fj_14_258780
crossref_primary_10_1053_j_ajkd_2014_09_015
crossref_primary_10_1177_0091270011413588
crossref_primary_10_1016_j_yrtph_2013_10_006
crossref_primary_10_1038_s41581_019_0111_1
crossref_primary_10_1053_j_ackd_2012_10_004
crossref_primary_10_3346_jkms_2018_33_e298
crossref_primary_10_1007_s11095_019_2593_8
crossref_primary_10_1002_jcph_1818
crossref_primary_10_1592_phco_29_5_562
crossref_primary_10_1038_ki_2012_193
crossref_primary_10_1093_ndt_gft091
crossref_primary_10_1111_bcp_12733
crossref_primary_10_1038_ki_2013_399
crossref_primary_10_1093_toxsci_kfw193
crossref_primary_10_1186_s41100_016_0091_6
crossref_primary_10_1016_j_crphar_2021_100020
crossref_primary_10_1194_jlr_P040022
crossref_primary_10_1016_j_nephro_2014_12_006
crossref_primary_10_2165_11593320_000000000_00000
Cites_doi 10.1016/j.pharmthera.2005.05.010
10.1038/sj.bjp.0704951
10.1248/bpb.25.1077
10.1038/sj.clpt.1996.43
10.1124/dmd.104.000521
10.1038/sj.bjp.0706138
10.1016/j.ajkd.2003.07.019
10.1038/clpt.1993.198
10.1016/j.vascn.2006.07.002
10.1016/S0009-9236(03)00056-0
10.1681/ASN.V122326
10.1681/ASN.2006060610
10.1681/ASN.2006010035
10.1074/jbc.M106286200
10.1124/dmd.107.018192
10.1074/jbc.M111013200
10.1023/A:1016044032571
10.1016/S0090-9556(24)15079-9
10.1016/S0022-3565(25)21242-3
10.1016/S0009-9236(03)00015-8
ContentType Journal Article
Copyright 2008 Elsevier B.V.
The Japanese Pharmacological Society 2008
Copyright_xml – notice: 2008 Elsevier B.V.
– notice: The Japanese Pharmacological Society 2008
CorporateAuthor Division of Nephrology and Transplantation
Scarborough
Maine Medical Center Research Institute
Service de Nephrologie et Centre de Recherche Guy-Bernier
Hopital Maisonneuve-Rosemont
Department of Medicine
Center for Clinical and Translational Research
Maine Medical Center
Departeinent de Pharmacologie
Universite de Montreal
CorporateAuthor_xml – name: Maine Medical Center Research Institute
– name: Scarborough
– name: Division of Nephrology and Transplantation
– name: Service de Nephrologie et Centre de Recherche Guy-Bernier
– name: Department of Medicine
– name: Hopital Maisonneuve-Rosemont
– name: Maine Medical Center
– name: Departeinent de Pharmacologie
– name: Universite de Montreal
– name: Center for Clinical and Translational Research
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
DOI 10.1254/jphs.08042FP
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList


MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1347-8648
EndPage 163
ExternalDocumentID oai_doaj_org_article_a3d38deeb21346408ee2e7a18543ed5f
18845914
10_1254_jphs_08042FP
cf6scien_2008_010802_002_0157_016399599
article_jphs_108_2_108_08042FP_article_char_en
S1347861319313507
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.GJ
0R~
0SF
29L
2WC
3O-
4.4
457
53G
5GY
5RE
6I.
AACTN
AAEDT
AAEDW
AAFTH
AAIKJ
AALRI
AAXUO
ABMAC
ACGFO
ACGFS
ADBBV
ADEZE
AENEX
AEXQZ
AFTJW
AGHFR
AHPSJ
AITUG
AL-
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BCNDV
BKOMP
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FDB
GROUPED_DOAJ
GX1
HH5
IPNFZ
JMI
JSF
JSH
KQ8
M41
MOJWN
M~E
NCXOZ
O9-
OK1
RIG
RJT
RNS
ROL
RZJ
SSZ
TKC
TR2
W2D
X7M
XSB
ZGI
ZXP
AAYWO
ACVFH
ADCNI
ADVLN
AEUPX
AFJKZ
AFPUW
AIGII
AKBMS
AKRWK
AKYEP
APXCP
OVT
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c735t-e61477e0ce72cf2a2b33f3a7eeb5a1d157c9382d2fe6002cccfeda0fb13fa6473
IEDL.DBID DOA
ISSN 1347-8613
IngestDate Mon Sep 08 19:52:56 EDT 2025
Fri Jul 11 12:01:08 EDT 2025
Sat Sep 28 08:36:10 EDT 2024
Tue Jul 01 01:26:56 EDT 2025
Thu Apr 24 22:52:10 EDT 2025
Thu Jul 10 16:10:40 EDT 2025
Wed Sep 03 06:30:16 EDT 2025
Fri Feb 23 02:27:12 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords hemodialysis
cytochrome P450
end-stage renal disease
gene expression
drug metabolism
Language English
License http://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c735t-e61477e0ce72cf2a2b33f3a7eeb5a1d157c9382d2fe6002cccfeda0fb13fa6473
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/a3d38deeb21346408ee2e7a18543ed5f
PMID 18845914
PQID 69698549
PQPubID 23479
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_a3d38deeb21346408ee2e7a18543ed5f
proquest_miscellaneous_69698549
pubmed_primary_18845914
crossref_citationtrail_10_1254_jphs_08042FP
crossref_primary_10_1254_jphs_08042FP
medicalonline_journals_cf6scien_2008_010802_002_0157_016399599
jstage_primary_article_jphs_108_2_108_08042FP_article_char_en
elsevier_sciencedirect_doi_10_1254_jphs_08042FP
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2008-00-00
PublicationDateYYYYMMDD 2008-01-01
PublicationDate_xml – year: 2008
  text: 2008-00-00
PublicationDecade 2000
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle Journal of Pharmacological Sciences
PublicationTitleAlternate J Pharmacol Sci
PublicationYear 2008
Publisher Elsevier B.V
The Japanese Pharmacological Society
Elsevier
Publisher_xml – name: Elsevier B.V
– name: The Japanese Pharmacological Society
– name: Elsevier
References 4 Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis. 2003;42:906–925.
12 Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006;17:2363–2367.
19 Taburet AM, Vincent I, Perello L, Coret B, Baune B, Furlan V. Impairment of drug biotransformation in renal disease an in vitro model. Clin Pharmacol Ther. 1996;59:136.
9 Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL, et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther. 2003;73:475–477.
1 Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 2005;144:1067–1077.
13 Michaud J, Naud J, Chouinard J, Desy F, Leblond FA, Desbiens K. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2006;17:3041–3048.
10 Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003;73:427–434.
16 Guillen C, Martinez P, de Gortazar AR, Martinez ME, Esbrit P. Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells. J Biol Chem. 2002;277:28109–28117.
18 Yoshitani T, Yagi H, Inotsume N, Yasuhara M. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull. 2002;25:1077–1083.
6 Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12:326–332.
14 Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem. 2001;276:39638–39644.
20 Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res. 1996;13:1559–1564.
8 Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004;32:1239–1246.
7 Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Down-regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators. Br J Pharmacol. 2002;137:1039–1046.
2 Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008;36:124–128.
5 Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000;28:1317–1320.
11 Kim YG, Shin JG, Shin SG, Jang IJ, Kim S, Lee JS, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther. 1993;54:612–620.
3 Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1–11.
17 Terao N, Shen DD. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther. 1985;233:277–284.
15 Michaud J, Leblond FA, Naud J, Boisvert C, Desbiens K, Nicoll-Griffith DA, et al. Use of a fluorescent substrate for the selective quantification of rat CYP3A in the liver and the intestine. J Pharmacol Toxicol Methods. 2007;55:209–213.
12
13
14
15
16
18
19
LEBLOND F A (5) 2000; 28
1
2
3
4
6
7
8
9
Terao N., Shen D. D. (17) 1985; 233
(11) 1993; 54
20
10
References_xml – reference: 13 Michaud J, Naud J, Chouinard J, Desy F, Leblond FA, Desbiens K. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2006;17:3041–3048.
– reference: 11 Kim YG, Shin JG, Shin SG, Jang IJ, Kim S, Lee JS, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther. 1993;54:612–620.
– reference: 19 Taburet AM, Vincent I, Perello L, Coret B, Baune B, Furlan V. Impairment of drug biotransformation in renal disease an in vitro model. Clin Pharmacol Ther. 1996;59:136.
– reference: 6 Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12:326–332.
– reference: 9 Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL, et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther. 2003;73:475–477.
– reference: 14 Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem. 2001;276:39638–39644.
– reference: 17 Terao N, Shen DD. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther. 1985;233:277–284.
– reference: 12 Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006;17:2363–2367.
– reference: 18 Yoshitani T, Yagi H, Inotsume N, Yasuhara M. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull. 2002;25:1077–1083.
– reference: 3 Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1–11.
– reference: 5 Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000;28:1317–1320.
– reference: 20 Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res. 1996;13:1559–1564.
– reference: 10 Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003;73:427–434.
– reference: 15 Michaud J, Leblond FA, Naud J, Boisvert C, Desbiens K, Nicoll-Griffith DA, et al. Use of a fluorescent substrate for the selective quantification of rat CYP3A in the liver and the intestine. J Pharmacol Toxicol Methods. 2007;55:209–213.
– reference: 1 Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 2005;144:1067–1077.
– reference: 2 Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008;36:124–128.
– reference: 7 Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Down-regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators. Br J Pharmacol. 2002;137:1039–1046.
– reference: 16 Guillen C, Martinez P, de Gortazar AR, Martinez ME, Esbrit P. Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells. J Biol Chem. 2002;277:28109–28117.
– reference: 4 Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis. 2003;42:906–925.
– reference: 8 Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004;32:1239–1246.
– ident: 3
  doi: 10.1016/j.pharmthera.2005.05.010
– ident: 7
  doi: 10.1038/sj.bjp.0704951
– ident: 18
  doi: 10.1248/bpb.25.1077
– ident: 19
  doi: 10.1038/sj.clpt.1996.43
– ident: 8
  doi: 10.1124/dmd.104.000521
– ident: 1
  doi: 10.1038/sj.bjp.0706138
– ident: 4
  doi: 10.1016/j.ajkd.2003.07.019
– volume: 54
  start-page: 612
  issn: 0009-9236
  issue: 6
  year: 1993
  ident: 11
  doi: 10.1038/clpt.1993.198
– ident: 15
  doi: 10.1016/j.vascn.2006.07.002
– ident: 10
  doi: 10.1016/S0009-9236(03)00056-0
– ident: 6
  doi: 10.1681/ASN.V122326
– ident: 12
  doi: 10.1681/ASN.2006060610
– ident: 13
  doi: 10.1681/ASN.2006010035
– ident: 14
  doi: 10.1074/jbc.M106286200
– ident: 2
  doi: 10.1124/dmd.107.018192
– ident: 16
  doi: 10.1074/jbc.M111013200
– ident: 20
  doi: 10.1023/A:1016044032571
– volume: 28
  start-page: 1317
  issn: 0090-9556
  issue: 11
  year: 2000
  ident: 5
  doi: 10.1016/S0090-9556(24)15079-9
– volume: 233
  start-page: 277
  issn: 0022-3565
  issue: 2
  year: 1985
  ident: 17
  doi: 10.1016/S0022-3565(25)21242-3
– ident: 9
  doi: 10.1016/S0009-9236(03)00015-8
SSID ssj0028016
ssib002822155
ssib044745378
ssib058493307
Score 2.0844877
Snippet Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study...
SourceID doaj
proquest
pubmed
crossref
medicalonline
jstage
elsevier
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 157
SubjectTerms Aged
Aged, 80 and over
Animals
Aryl Hydrocarbon Hydroxylases - metabolism
Cells, Cultured
Cytochrome P-450 CYP1A2 - metabolism
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme System - genetics
Cytochrome P-450 Enzyme System - metabolism
cytochrome P450
Cytochrome P450 Family 2
Cytochromes
Diterpenes - pharmacology
Down-Regulation
drug metabolism
end-stage renal disease
Female
gene expression
Gene Expression Regulation, Enzymologic
hemodialysis
Hepatocytes - drug effects
Hepatocytes - enzymology
Humans
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - therapy
Liver - drug effects
Liver - enzymology
Male
Membrane Proteins - metabolism
Middle Aged
NF-kappa B - antagonists & inhibitors
NF-kappa B - metabolism
Rats
Rats, Sprague-Dawley
Renal Dialysis
RNA, Messenger - metabolism
Steroid 16-alpha-Hydroxylase - metabolism
Uremia - blood
Uremia - therapy
Title Effect of Hemodialysis on Hepatic Cytochrome P450 Functional Expression
URI https://dx.doi.org/10.1254/jphs.08042FP
https://www.jstage.jst.go.jp/article/jphs/108/2/108_08042FP/_article/-char/en
http://mol.medicalonline.jp/en/journal/download?GoodsID=cf6scien/2008/010802/002&name=0157-0163e
https://www.ncbi.nlm.nih.gov/pubmed/18845914
https://www.proquest.com/docview/69698549
https://doaj.org/article/a3d38deeb21346408ee2e7a18543ed5f
Volume 108
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Pharmacological Sciences, 2008, Vol.108(2), pp.157-163
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9MwFLfQTkgI8U1hDB9gFxbq2E4cH0CCqaVCGuphk3azHMfWNrFkWjuJXvjbeS92WnqouHCopTZPcfPey_uw3_uZkHe1x1PfKlxesiyTPDSZLmuZKYkBMAuFdtjgfPKjnJ3J7-fF-V9HfWFNWIQHjowbW9GIqvGQAOZClpJV3nOvLLgZKXxTBLS-TLMhmUqpFtjdvq9ISLDB4LFSyTtkQ-Orm4vFR4iTJJ_Ot5xRj9m_7ZOuIELD1vsH13HXJKJX7A5Ge6c0fUQepmiSfolP8Zjc8-0TcjiPcNSrI3q66a5aHNFDOt8AVa-ekm8Ruph2gc78dYctJIhPQrsWvmOltaPHq2XnLhDSgM5lwegU3GBcPaSTX6mGtn1GzqaT0-NZlg5WyJwSxTLz4JOV8sx5xV3gltdCBGEVcLmweZMXymlR8YYHj9t2zrngG8tCnYtgS6nEc7LXdq1_SSgva-aE55WruYTYyFaqDrV2VnG4tWYj8mHgsHEJdRwPv_hpMPsAeRiUh0nyGJH3a-qbiLaxg-4rCmtNgxjZ_Q-gOSZpjvmX5ozIeBC1SeFGDCPgVpc7pv0UNWI98TBXT5WzyvB-TPTry9hBB2ZoRD5vKZJJ9mJhXCj7v5BOBcXCT24YfkAYMGAcWWg9Im8HzTNgBnBvx7a-u1uYUpcaHgwoXkSF3PCvqmShc_nqf_DsNbkfC2ZwDWqf7C1v7_wbiMqW9UH_Ah6gZyxgPPk9-QMueDYj
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Hemodialysis+on+Hepatic+Cytochrome+P450+Functional+Expression&rft.jtitle=Journal+of+pharmacological+sciences&rft.au=Jos%C3%A9e+Michaud&rft.au=Thomas+D.+Nolin&rft.au=Judith+Naud&rft.au=M%C3%A9lina+Dani&rft.date=2008&rft.pub=Elsevier&rft.issn=1347-8613&rft.volume=108&rft.issue=2&rft.spage=157&rft.epage=163&rft_id=info:doi/10.1254%2Fjphs.08042FP&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_a3d38deeb21346408ee2e7a18543ed5f
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-8613&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-8613&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-8613&client=summon